Semax is one of the more storied "cognitive" peptides, with decades of use in Russia and a research base that's intriguing but geographically narrow. Here's what's actually known.

What Semax is

Semax is a synthetic peptide developed in Russia, where it carries regulatory approval for certain neurological indications. It's studied in the context of cognition, attention, and neuroprotection.

The research picture

Much of the Semax literature comes from Russian research institutions, and while it's substantial by the standards of research peptides, it hasn't been widely replicated in large international trials. That's the recurring caveat with this category: promising signals, limited independent validation.

Status

Semax is not FDA-approved in the US and was among the peptides swept into the 2023 restriction and discussed in the 2026 reconsideration. Its status here is unsettled, see 2026 Updates.

A longer track record than most research peptides, mostly outside the US and mostly unreplicated at scale.

Bottom line

Compare it with Selank in our Selank vs Semax piece and read the full guide, then bring any questions to a licensed provider.